Sugi Predict

Sugi Predict / Compounds / SCHEMBL1502109

SCHEMBL1502109

SCHEMBL1502109

Oc1ccccc1-c1c[nH]cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 5/20 0.47
▸ BRD4 O60885 1/20 0.42
▸ NR1I2 O75469 1/20 0.42
▸ SMARCA2 P51531 1/20 0.42
▸ SMARCA4 P51532 1/20 0.42
▸ PBRM1 Q86U86 1/20 0.42
▸ DCUN1D1 Q96GG9 1/20 0.42
▸ ALOX15 P16050 4/20 0.41
▸ HSD17B10 Q99714 3/20 0.41
▸ TP53 P04637 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ SMN1; SMN2 Q16637 4/20 0.40
▸ HPGD P15428 3/20 0.40
▸ MAPT P10636 3/20 0.40
▸ NFKB1 P19838 2/20 0.40
▸ NFKB2 Q00653 2/20 0.40
▸ RELA Q04206 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ RAB9A P51151 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13564302 0.81 IDO1 (0.44) IDO1BRD4NR1I2SMARCA2SMARCA4
SCHEMBL7027339 0.78 TYR (0.43) SMN1; SMN2HPGDMAPTNFKB1NFKB2
SCHEMBL12676617 0.78 ALOX5 (0.46) IDO1BRD4NR1I2SMARCA2SMARCA4
SCHEMBL1502239 0.78 IDO1 (0.41) IDO1ALOX15HSD17B10TP53MAPK1
SCHEMBL1949938 0.77 GAA (0.41) IDO1HPGDMAPTALDH1A1CYP19A1
SCHEMBL12676834 0.77 RIPK1 (0.32) ALOX15TP53SMN1; SMN2MAPTNFKB1
SCHEMBL26259557 0.77 IKBKE (0.32) MEN1KMT2A
SCHEMBL26259398 0.77 MEN1 (0.33) BRD4ALOX15SMN1; SMN2MEN1KMT2A
SCHEMBL1501942 0.76 IDO1 (0.47) IDO1DCUN1D1ALOX15HSD17B10SMN1; SMN2
SCHEMBL1501919 0.76 IDO1 (0.43) IDO1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4525821-A1 COMPOSITIONS THAT ENHANCE THE COOLING EFFECT Firmenich Incorporated (US) 2025-03-26 — — EP claimed
WO-2024011086-A1 COMPOSITIONS THAT ENHANCE THE COOLING EFFECT FIRMENICH INCORPORATED (US) 2024-01-11 — — WO claimed
US-9174942-B2 IDO inhibitors NEWLINK GENETICS CORPORATION (US) 2015-11-03 — — US claimed
US-20140323740-A1 IDO Inhibitors NEWLINK GENETICS CORPORATION (US) 2014-10-30 — — US claimed
US-7037654-B2 Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents ACLARA BIOSCIENCES, INC. (US) 2006-05-02 — — US claimed
US-20050053939-A1 Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents MONOGRAM BIOSCIENCES, INC. 2005-03-10 — — US claimed
WO-2003042658-A2 METHODS AND COMPOSITIONS FOR ENHANCING DETECTION IN DETERMINATIONS EMPLOYING CLEAVABLE ELECTROPHORETIC TAG REAGENTS ACLARA BIOSCIENCES, INC. (US) 2003-05-22 — — WO claimed
US-20250145598-A1 ACID CERAMIDASE INHIBITORS AND USES THEREOF UNIV CALIFORNIA (US) 2025-05-08 — — US disclosed
EP-4476217-A1 MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF C4 Therapeutics, Inc. (US) 2024-12-18 — — EP disclosed
EP-4387617-A1 ACID CERAMIDASE INHIBITORS AND USES THEREOF The Regents of the University of California (US) 2024-06-26 — — EP disclosed
CN-111004167-B Salts and prodrugs of 1-methyl-D-tryptophan 新联基因公司 2024-03-22 — — CN disclosed
WO-2023154417-A1 MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF C4 THERAPEUTICS, INC. (US) 2023-08-17 — — WO disclosed
WO-2023023156-A1 ACID CERAMIDASE INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-02-23 — — WO disclosed
US-20070190358-A1 Cyclometalated transition metal complex and organic electroluminescence device using the same SAMSUNG DISPLAY CO., LTD. (KR) 2007-08-16 — — US disclosed
US-20070190358-A1 Cyclometalated transition metal complex and organic electroluminescence device using the same SAMSUNG DISPLAY CO., LTD. (KR) 2007-08-16 — — US disclosed
US-7037654-B2 Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents ACLARA BIOSCIENCES, INC. (US) 2006-05-02 — — US disclosed
US-20050053939-A1 Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents MONOGRAM BIOSCIENCES, INC. 2005-03-10 — — US disclosed
US-20040096825-A1 METHODS AND COMPOSITIONS FOR ENHANCING DETECTION IN DETERMINATIONS EMPLOYING CLEAVABLE ELECTROPHORETIC TAG REAGENTS ACLARA BIOSCIENCES, INC. 2004-05-20 — — US disclosed
WO-2003042658-A2 METHODS AND COMPOSITIONS FOR ENHANCING DETECTION IN DETERMINATIONS EMPLOYING CLEAVABLE ELECTROPHORETIC TAG REAGENTS ACLARA BIOSCIENCES, INC. (US) 2003-05-22 — — WO disclosed
WO-1999001768-A1 PEROXIDASE-CATALYSED FLUORESCENCE NYCOMED AMERSHAM PLC (GB) 1999-01-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145598-A1 ACID CERAMIDASE INHIBITORS AND USES THEREOF ASAH2, ASAH1, ACER2 IDO1 1702/4885BRD4 2037/4885NR1I2 4084/4885
US-20140323740-A1 IDO Inhibitors IDO1, IDO2, INMT IDO1 1/4885BRD4 927/4885NR1I2 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.